ILMN
Illumina, Inc. · Healthcare · Medical - Diagnostics & Research
Señales de momentum (gestores comparables):
amplitud de titulares -4.2% ·
flujo de acciones +4.1% ·
nuevas posiciones netas -8.7%
— fórmula
Acumulación concentrada — aumento de acciones entre menos titulares
Todas las cifras de propiedad: únicamente gestores 13F seguidos, posiciones en acciones ordinarias, período de referencia Q3 2025
| Trimestre | Titulares | Δ | Acciones | Valor declarado | Nuevo | Cierres |
|---|---|---|---|---|---|---|
| Q2 2026 | 164 | +8 | 117.28M | $20.62B | +11 | −2 |
| Q1 2026 | 158 | -5 | 113.90M | $14.03B | +5 | −11 |
| Q4 2025 | 162 | 0 | 124.91M | $16.38B | +2 | −1 |
| Q3 2025 | 23 | -1 | 78.13M | $7.41B | +1 | −3 |
| Q2 2025 | 22 | 0 | 71.58M | $6.83B | +1 | −1 |
| Q1 2025 | 19 | 0 | 39.00M | $3.09B | +1 | −1 |
| Q4 2024 | 19 | 0 | 37.37M | $4.99B | +2 | −2 |
| Q3 2024 | 18 | 0 | 20.75M | $2.70B | +1 | −1 |
| Q2 2024 | 18 | — | 22.19M | $2.32B | — | — |
| # | Gestor | Acciones | Δ acciones | Valor | Su ponderación | Mantenida | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Capital World Investors ✦ | 19.98M | +20.0% | $1.90B | 0.3% | ▲ Add | 6 | SEC ↗ |
| 2 | BlackRock ✦ (pasivo) | 18.69M | -3.5% | $1.77B | 0.0% | ▼ Trim | 2 | SEC ↗ ×21 |
| 3 | The Vanguard Group ✦ (pasivo) | 14.63M | -3.5% | $1.39B | 0.0% | ▼ Trim | 2 | SEC ↗ ×6 |
| 4 | State Street Global Advisors ✦ (pasivo) | 6.00M | +6.8% | $569.80M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 5 | AQR Capital Management ✦ | 3.40M | +3.1% | $315.91M | 0.2% | ▲ Add | 6 | SEC ↗ ×7 |
| 6 | Geode Capital Management ✦ (pasivo) | 2.74M | -4.5% | $259.30M | 0.0% | ▼ Trim | 6 | SEC ↗ ×2 |
| 7 | PRIMECAP Management ✦ | 1.89M | -3.7% | $179.04M | 0.1% | ▼ Trim | 6 | SEC ↗ |
| 8 | Baillie Gifford ✦ | 1.69M | -3.1% | $160.19M | 0.1% | ▼ Trim | 6 | SEC ↗ ×4 |
| 9 | JPMorgan Chase ✦ | 1.67M | — | $158.16M | 0.0% | n/c | 1 | SEC ↗ ×28 |
| 10 | Fidelity (FMR) ✦ | 1.57M | +39.2% | $149.17M | 0.0% | ▲ Add | 2 | SEC ↗ ×5 |
| 11 | Morgan Stanley ✦ | 1.52M | — | $144.69M | 0.0% | n/c | 1 | SEC ↗ ×18 |
| 12 | ARK Investment Management ✦ | 1.47M | +25.7% | $139.40M | 0.8% | ▲ Add | 4 | SEC ↗ |
| 13 | Renaissance Technologies ✦ | 1.20M | +17.9% | $114.43M | 0.2% | ▲ Add | 6 | SEC ↗ |
| 14 | Goldman Sachs Group ✦ | 501.50K | — | $47.63M | 0.0% | n/c | 1 | SEC ↗ ×3 |
| 15 | Millennium Management ✦ | 330.74K | +172.2% | $31.41M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 16 | Gotham Asset Management ✦ | 292.69K | +97.5% | $27.80M | 0.1% | ▲ Add | 6 | SEC ↗ |
| 17 | Arrowstreet Capital ✦ | 227.64K | -32.0% | $21.62M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 18 | T. Rowe Price ✦ | 129.56K | +7.2% | $12.30M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 19 | Glenview Capital ✦ | 101.72K | Nuevo | $9.66M | 0.2% | New | 1 | SEC ↗ |
| 20 | Two Sigma Investments ✦ | 44.40K | -80.5% | $4.22M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 21 | Citadel Advisors ✦ | 42.80K | +59.2% | $4.07M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 22 | Wellington Management ✦ | 21.11K | -28.3% | $2.00M | 0.0% | ▼ Trim | 6 | SEC ↗ ×2 |
| 23 | D. E. Shaw & Co. ✦ | 9.78K | -45.1% | $929,186 | 0.0% | ▼ Trim | 6 | SEC ↗ |
«Su ponderación» = la participación de la posición en el valor de renta variable 13F declarado por ese gestor — la medida de convicción. ✦ = gestor seleccionado.
Nuevos compradores
| Glenview Capital | $9.66M | 0.2% |
Posición cerrada
| Duquesne Family Office | $28.68M | era 0.7% |
| Norges Bank | $22.86M | era 0.0% |
| Marshall Wace | $5.69M | era 0.0% |
Contexto de mercado completo: entre TODOS los filers 13F (datos estructurados SEC, Q1 2026): 837 tenedores, 154.80M acciones, $18.58B declarado. Este es un período diferente y anterior al de las cifras del universo rastreado que figuran arriba, y ambos nunca se mezclan.
Qué otros valores suelen tener también los tenedores rastreados de este activo — recuentos de cotenencia, no relaciones fundamentales.
Compras en mercado abierto (P)
Sin compras en mercado abierto por parte de insiders en nuestra ventana de cobertura.
Ventas en mercado abierto (S)
Director · 7.50K acc. · $1.63M
Director · 11.35K acc. · $2.49M
Director · 100.65K acc. · $21.98M
Director · 13.26K acc. · $2.87M
Director · 9.96K acc. · $2.21M
Director · 6.66K acc. · $1.47M
Director · 13.72K acc. · $3.01M
Director · 9.72K acc. · $2.12M
Director · 14.20K acc. · $3.08M
Director · 8.44K acc. · $1.82M
Las adjudicaciones, ejercicios y retenciones fiscales nunca se contabilizan aquí como compras o ventas. Metodología